Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery First-in-class intraoperative vascular graft treatment shown to reduce the risk of graft failure. Results presented at European Association for Cardio-Thoracic Surgery Annual Meeting in Barcelona. JUPITER, FL – October 4, 2016...

JUPITER, Fla., Jan. 4, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced enrollment of the first subject in their DuraGraft® CABG European Registry. The registry will evaluate the company’s flagship...

Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft Registry.